ArticleEvidence-based complementary and alternative medicine : eCAM2023
Clinical Study of 3DCRT Combined with SBRT in the Treatment of Patients with EGFR Mutation Oligometastatic Non-Small Cell Lung Cancer.
Article in Evidence-based complementary and alternative medicine : eCAM, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is one of the malignant tumors with the highest morbidity and mortality in my country and the world. Among them, non-small-cell lung cancer (NSCLC) accounts for about 80%. For patients who are diagnosed with NSCLC and have epidermal growth factor receptor, EGFR gene-sensitive mutations The treatment is particularly important. Aims: To investigate the efficacy and prognosis of 3DCRT combined with local SBRT in patients with EGFR mutation oligometastatic NSCLC. Materials and Methods: Eighty patients with EGFR mutation oligometastatic NSCLC were selected by random remainder grouping method. 3DCRT combined with SBRT is effective and safer in patients with EGFR-mutant oligometastatic NSCLC, and significantly improves the patient's immune and tumor marker levels. It has a certain reference value in the clinical treatment of EGFR-mutant oligometastatic NSCLC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.